Sarepta faces FDA scrutiny over Elevidys as analysts downgrade stock and warn of long-term debt risks amid market uncertainty ...

Sarepta stock took another dive Monday after the biotech company refused the FDA's request to voluntarily stop all shipments ...

The crisis over Sarepta Therapeutics' Duchenne therapy offers a valuable lesson: Listening to critics, and responding with ...

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...

Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $164.08, a high estimate of $185.00, and a low estimate of $128.00.

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

9 analysts have expressed a variety of opinions on Sarepta Therapeutics (NASDAQ:SRPT) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table ...

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

A company spokesperson told Bloomberg that a 51-year-old patient died of acute liver failure last month in an early-stage ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts are typically employed by large Wall Street banks and tasked with ...

Across the recent three months, 26 analysts have shared their insights on Sarepta Therapeutics (NASDAQ:SRPT), expressing a variety of opinions spanning from bullish to bearish.The table below ...